Better Growth Stock: AbbVie vs. Abbott Laboratories
Drugmaker AbbVie (NYSE: ABBV) spun off from Abbott Laboratories (NYSE: ABT) at the start of 2013. The growth-oriented pharma business has become a beast, generating more than $58 billion in revenue last year -- far more than Abbott's top line, which totaled just under $44 billion.
But today, AbbVie faces some challenges as its top-selling drug Humira is losing patent protection and its sales have been declining sharply. Abbott, meanwhile, isn't just some stale business. Its diabetes products have been generating impressive growth, and the company is also getting into consumer wearables.
Moving forward, which business is the better option for growth-oriented investors? Let's see.
Source Fool.com
Abbott Laboratories Stock
€98.38
-0.130%
Abbott Laboratories is currently one of the favorites of our community with 16 Buy predictions and no Sell predictions.
With a target price of 116 € there is a slightly positive potential of 17.91% for Abbott Laboratories compared to the current price of 98.38 €.
